The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes

Infection and Immunity

Volumn 77, Issue 11, 2009, Pages 4714-4723

  Nguyen, Melissa L ^a,b   Terzyan, Simon ^b   Ballard, Jimmy D ^a   James, Judith A ^b   Farris, A Darise ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; ANTIBODY; EDEMA FACTOR ANTIBODY; EDEMA TOXIN; EPITOPE; LETHAL TOXIN; NEUTRALIZING ANTIBODY; RECOMBINANT EDEMA FACTOR; RECOMBINANT LETHAL FACTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BACILLUS; BACTERIAL SPORE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES; ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, B-LYMPHOCYTE; FEMALE; MICE; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

EID: 70350446692     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00749-09     Document Type: Article

References (39)

1. Albrecht, M. T., H. Li, E. D. Williamson, C. S. LeButt, H. C. Flick-Smith, C. P. Quinn, H. Westra, D. Galloway, A. Mateczun, S. Goldman, H. Groen, and L. W. Baillie. 2007. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun. 75:5425-5433.
2. Baillie, L. 2001. The development of new vaccines against Bacillus anthracis. J. Appl. Microbiol. 91:609-613.
3. Baillie, L., R. Hebdon, H. Flick-Smith, and D. Williamson. 2003. Characterisation of the immune response to the UK human anthrax vaccine. FEMS Immunol. Med. Microbiol. 36:83-86.
4. Baillie, L. W., K. Fowler, and P. C. Turnbull. 1999. Human immune responses to the UK human anthrax vaccine. J. Appl. Microbiol. 87:306-308.
5. Berman, H. M., J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, and P. E. Bourne. 2000. The Protein Data Bank. Nucleic Acids Res. 28:235-242.
6. Bragg, T. S., and D. L. Robertson. 1989. Nucleotide sequence and analysis of the lethal factor gene (lef) from Bacillus anthracis. Gene 81:45-54.
7. Brossier, F., M. Levy, A. Landier, P. Lafaye, and M. Mock. 2004. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun. 72:6313-6317.
8. Dixon, T. C., M. Meselson, J. Guillemin, and P. C. Hanna. 1999. Anthrax. N. Engl. J. Med. 341:815-826.
9. Dong, D. Y., J. J. Xu, X. H. Song, L. Fu, and W. Chen. 2005. Expression and analysis of biological activity of the recombination anthrax edema factor. Wei Sheng Wu Xue Bao 45:459-462. (In Chinese.)
10. Drum, C. L., S. Z. Yan, J. Bard, Y. Q. Shen, D. Lu, S. Soelaiman, Z. Grabarek, A. Bohm, and W. J. Tang. 2002. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature 415:396-402.
11. Farris, A. D., L. Brown, P. Reynolds, J. B. Harley, J. A. James, R. H. Scofield, J. McCluskey, and T. P. Gordon. 1999. Induction of autoimmunity by multivalent immunodominant and subdominant T cell determinants of La (SSB). J. Immunol. 162:3079-3087.
12. Firoved, A. M., G. F. Miller, M. Moayeri, R. Kakkar, Y. Shen, J. F. Wiggins, E. M. McNally, W. J. Tang, and S. H. Leppla. 2005. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am. J. Pathol. 167:1309-1320.
13. Firoved, A. M., M. Moayeri, J. F. Wiggins, Y. Shen, W. J. Tang, and S. H. Leppla. 2007. Anthrax edema toxin sensitizes DBA/2J mice to lethal toxin. Infect. Immun. 75:2120-2125.
14. Flick-Smith, H. C., E. L. Waters, N. J. Walker, J. Miller, A. J. Stagg, M. Green, and E. D. Williamson. 2005. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb. Pathog. 38:33-40.
15. Friedlander, A. M., P. R. Pittman, and G. W. Parker. 1999. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 282: 2104-2106.
16. Guarner, J., J. A. Jernigan, W. J. Shieh, K. Tatti, L. M. Flannagan, D. S. Stephens, T. Popovic, D. A. Ashford, B. A. Perkins, and S. R. Zaki. 2003. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am. J. Pathol. 163:701-709.
17. Gupta, P., A. Singh, V. Chauhan, and R. Bhatnagar. 2001. Involvement of residues 147VYYEIGK153 in binding of lethal factor to protective antigen of Bacillus anthracis. Biochem. Biophys. Res. Commun. 280:158-163.
18. Juris, S. J., R. A. Melnyk, R. E. Bolcome III, J. Chan, and R. J. Collier. 2007. Cross-linked forms of the isolated N-terminal domain of the lethal factor are potent inhibitors of anthrax toxin. Infect. Immun. 75:5052-5058.
19. Kobiler, D., Y. Gozes, H. Rosenberg, D. Marcus, S. Reuveny, and Z. Altboum. 2002. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect. Immun. 70:544-560.
20. Kumar, P., N. Ahuja, and R. Bhatnagar. 2001. Purification of anthrax edema factor from Escherichia coli and identification of residues required for binding to anthrax protective antigen. Infect. Immun. 69:6532-6536.
21. Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 79:3162-3166.
22. Little, S. F., S. H. Leppla, J. W. Burnett, and A. M. Friedlander. 1994. Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies. Biochem. Biophys. Res. Commun. 199:676-682.
23. Little, S. F., S. H. Leppla, and A. M. Friedlander. 1990. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect. Immun. 58:1606-1613.
24. McClain, M. T., L. D. Heinlen, G. J. Dennis, J. Roebuck, J. B. Harley, and J. A. James. 2005. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat. Med. 11:85-89.
25. McClain, M. T., B. D. Poole, B. F. Bruner, K. M. Kaufman, J. B. Harley, and J. A. James. 2006. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum. 54: 360-368.
26. Moayeri, M., and S. H. Leppla. 2009. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol. Aspects Med. [Epub ahead of print.] doi:10.1016/j.mam.2009.07.003.
27. Mock, M., and A. Fouet. 2001. Anthrax. Annu. Rev. Microbiol. 55:647-671.
28. Nguyen, M. L., S. R. Crowe, S. Kurella, S. Teryzan, B. Cao, J. D. Ballard, J. A. James, and A. D. Farris. 2009. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect. Immun. 77:162-169.
29. Pezard, C., M. Weber, J. C. Sirard, P. Berche, and M. Mock. 1995. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect. Immun. 63:1369-1372.
30. Pittman, P. R., P. H. Gibbs, T. L. Cannon, and A. M. Friedlander. 2001. Anthrax vaccine: short-term safety experience in humans. Vaccine 20:972-978.
31. Salles, I. I., D. E. Voth, S. C. Ward, K. M. Averette, R. K. Tweten, K. A. Bradley, and J. D. Ballard. 2006. Cytotoxic activity of Bacillus anthracis protective antigen observed in a macrophage cell line overexpressing ANTXR1. Cell. Microbiol. 8:1272-1281.
32. Staats, H. F., S. M. Alam, R. M. Scearce, S. M. Kirwan, J. X. Zhang, W. M. Gwinn, and B. F. Haynes. 2007. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect. Immun. 75:5443-5452.
33. Taft, S. C., and A. A. Weiss. 2008. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Clin. Vaccine Immunol. 15:71-75.
34. Tournier, J. N., A. Quesnel-Hellmann, J. Mathieu, C. Montecucco, W. J. Tang, M. Mock, D. R. Vidal, and P. L. Goossens. 2005. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J. Immunol. 174:4934-4941. (Pubitemid 40504578)
35. Turnbull, P. C., S. H. Leppla, M. G. Broster, C. P. Quinn, and J. Melling. 1988. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med. Microbiol. Immunol. 177:293-303.
36. Voth, D. E., E. E. Hamm, L. G. Nguyen, A. E. Tucker, I. I. Salles, W. Ortiz-Leduc, and J. D. Ballard. 2005. Bacillus anthracis oedema toxin as a cause of tissue necrosis and cell type-specific cytotoxicity. Cell. Microbiol. 7:1139-1149.
37. Wang, J. Y., and M. H. Roehrl. 2005. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med. Immunol. 4:4.
38. Zeng, M., Q. Xu, E. D. Hesek, and M. E. Pichichero. 2006. N-fragment of edema factor as a candidate antigen for immunization against anthrax. Vaccine 24:662-670. (Pubitemid 43017833)
39. Zhou, B., C. Carney, and K. D. Janda. 2008. Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin. Bioorg. Med. Chem. 16:1903-1913.